Latest revenue
$28.4K
as of 2026-03-31
Latest net income
$-3.2M
as of 2026-03-31
Net margin
-11367.0%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ASBP is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $7.3M
- Enterprise value
- $1.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.88×
- Dividend yield
- 0.0%
- 52-wk high
- $7.05
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 1.3M
5-year trend
What this company does
Item 1. Business. Overview Aspire is an early-stage biopharmaceutical company. As a Delaware corporation formed in February 2025, the Company engages in the business of developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Business Combination we were a privately held Puerto Rico corporation incorporated in September 2021. Our internet address is www.aspirebiolabs.com. Business Plan We expect to generate revenue through developing and marketing drugs and nutraceuticals using the technology for the novel sublingual delivery. Further, from time to time, we may enter into license or collaboration agreements with…
AI summary unavailable — showing raw filing excerpt
Generated from ASBP's filing dated 2026-03-30
Key risks
Item 1A. Risk Factors. As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this Item. Factors that could cause our actual results to differ materially from any forward-looking statements in this Report are any of the risks described in our final prospectus for our initial public offering filed with the SEC and the risks described in this Report and other reports we have filed with the Securities and Exchange Commission. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that…
AI summary unavailable — showing raw filing excerpt
Generated from ASBP's filing dated 2026-03-30
Profitability
Gross margin
-1.9%
Operating margin
-312016.9%
Net margin
-394725.1%
Return on equity
383.9%
90.1%Return on assets
-1865.7%
899.2%Leverage
Debt / equity
-1.21×
94.5%Debt / assets
585.9%
459.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $28.4K | — | $-3.2M | +79.8% | -11367.0% |
Q4 2025 2025-12-31 | — | — | $-4.7M | +60.7% | — |
Q3 2025 2025-09-30 | $1.9K | — | $-1.9M | -755.6% | -95337.1% |
Q2 2025 2025-06-30 | — | — | $-2.0M | -1944.2% | — |
Q1 2025 2025-03-31 | — | — | $-15.9M | -6801.9% | — |
Q4 2024 2024-12-31 | — | — | $-12.0M | — | — |
Q3 2024 2024-09-30 | — | — | $-216.3K | -212.3% | — |
Q2 2024 2024-06-30 | — | — | $-96.9K | -105.3% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ASBP — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for ASBP in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns ASBP
Institutional value
$232.2K
Total shares held
226.7K
Distinct holders
9
-21 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 191.5K | $197.2K | -2.3M (-92.4%) | Trimmed |
| 2 | Crewe Advisors LLC | 20.3K | $20.9K | -793.1K (-97.5%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 7.9K | $8.1K | — | New |
| 4 | VANGUARD FIDUCIARY TRUST CO | 2.9K | $2.9K | — | New |
| 5 | CITIGROUP INC | 1.8K | $1.9K | — | New |
| 6 | VALLEY WEALTH MANAGERS, INC. | 1.0K | $1.0K | -39.0K (-97.5%) | Trimmed |
| 7 | Caitong International Asset Management Co., Ltd | 1 | $1 | — | New |
| 8 | Avion Wealth | 1.4K | $1 | -52.8K (-97.5%) | Trimmed |
| 9 | SBI Securities Co., Ltd. | 1 | $1 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ASBP's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.